10-Q: Profound Medical Reports Wider Q2 Loss Amid Soaring Costs

Profound Medical Corp. reported a significantly wider net loss for Q2 2025, driven by substantial increases in operating expenses, despite revenue growth for the six-month period.

Summary

• Net loss for the three months ended June 30, 2025, widened to $15,695 thousand, a 127% increase from $6,919 thousand in the same period of 2024.
• For the six months ended June 30, 2025, net loss increased by 96% to $26,419 thousand, compared to $13,504 thousand in the prior year.
• Revenue for the three months ended June 30, 2025, was $2,211 thousand, a slight decrease of 1% from $2,233 thousand in Q2 2024, primarily due to reduced capital sales partially offset by higher recurring revenue in the United States.
• Six-month revenue increased by 32% to $4,832 thousand, up from $3,672 thousand in the prior year, driven by higher recurring revenue in the United States and capital sales overseas.
• Gross profit margin improved to 73% for Q2 2025 (from 64% in Q2 2024) and 72% for the six months (from 62% in H1 2024), attributed to capital equipment buyouts and improved manufacturing efficiency.
• Research and development (R&D) expenses surged by 45% to $6,098 thousand in Q2 2025 and 34% to $10,906 thousand for the six months, mainly due to increased headcount, CAPTAIN trial enrollment, and R&D initiatives.
• Selling, general and administrative (SG&A) expenses increased by 84% to $9,326 thousand in Q2 2025 and 78% to $17,537 thousand for the six months, driven by sales force expansion, commissions, travel, and marketing events.
• Cash balance decreased from $54,912 thousand as of December 31, 2024, to $35,195 thousand as of June 30, 2025.
• Net cash used in operating activities for the six months ended June 30, 2025, was $22,027 thousand, significantly higher than $10,748 thousand used in the prior year period.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significantly wider net loss, substantial increases in operating expenses leading to higher cash burn, a notable decrease in cash reserves, and the explicit projection of a financial covenant breach. While there was six-month revenue growth and improved gross margins, these positives are overshadowed by the company's deteriorating financial health and stated dependence on future financing.

Positives

• Six-month revenue increased by 32% to $4,832 thousand, indicating growth in product adoption over a longer period.
• Gross profit margin improved significantly to 73% in Q2 2025 and 72% for the six months, reflecting higher-margin product mix and manufacturing efficiencies.
• Continued investment in R&D, with expenses increasing by 34% for the six months, supports ongoing product development and clinical trials like CAPTAIN, which are crucial for future growth and reimbursement efforts.
• Expansion of sales force and commercialization efforts, as evidenced by the 78% increase in SG&A expenses for the six months, demonstrates commitment to market penetration for TULSA-PRO and Sonalleve.

Negatives

• Net loss more than doubled for both the three-month ($15,695 thousand) and six-month ($26,419 thousand) periods ended June 30, 2025, compared to the prior year.
• Operating expenses (R&D and SG&A) increased substantially, leading to a significant rise in overall costs and contributing to the wider net loss.
• Cash balance declined by approximately $19.7 million from December 31, 2024, to June 30, 2025, indicating a high cash burn rate.
• Net cash used in operating activities more than doubled to $22,027 thousand for the six months ended June 30, 2025, compared to the prior year.
• A material weakness in internal control over financial reporting related to revenue recognition was identified as of December 31, 2024, which is still undergoing remediation.

Risks

• Liquidity risk: Existing cash and product sales are expected to fund operations for at least the next 12 months, but the company's ability to achieve future strategic plans is dependent on obtaining additional financing or executing other strategic options by Q3 2026.
• Projected breach of CIBC Credit Agreement covenant: The company projects to be in violation of a financial covenant (unrestricted cash greater than EBITDA for the most recent nine-month period) by December 31, 2025, which could allow CIBC to declare outstanding debt immediately due and payable.
• Reliance on assumptions: Estimates for funding operating expenses and capital expenditures are based on assumptions that may prove incorrect, potentially leading to faster utilization of capital resources.
• Internal control weakness: A material weakness in internal control over financial reporting related to revenue recognition could result in misstatements of financial statements if remediation efforts are not fully effective and sustained.

Future Outlook

The company expects existing cash and product sales to fund operating expenses and capital expenditure requirements for at least the next 12 months. Expenses are anticipated to increase due to continued commercialization of TULSA-PRO and Sonalleve. The ability to accomplish all future strategic plans is dependent on obtaining additional financing or executing other strategic options by the third quarter of 2026. Management's remediation plan for the material weakness in internal control over financial reporting is expected to be completed during 2025.

Management Comments

• Management expects that existing cash and sales of products and services will enable the company to fund operating expenses and capital expenditure requirements for at least the next 12 months.
• Expenses are expected to increase, primarily due to the continued commercialization of TULSA-PRO and Sonalleve.
• The company's ability to accomplish all of its future strategic plans is dependent on obtaining additional financing or executing other strategic options by the third quarter of the year ending December 31, 2026.
• Management has evaluated the significance of the projected CIBC covenant breach and concluded that, if a waiver cannot be obtained, the company will have sufficient unrestricted cash to repay the total remaining outstanding debt obligation.

Industry Context

Profound Medical operates in the competitive and innovation-driven medical device industry, specializing in image-guided ablation therapies. The market for minimally invasive procedures, particularly in prostate health and women's health (uterine fibroids), is experiencing growth. TULSA-PRO's MRI-guided, incision-free approach positions it in a niche that emphasizes precision and patient recovery. The high R&D and SG&A expenditures are typical for companies in this stage, focusing on clinical validation, market penetration, and expanding product compatibility within existing healthcare imaging infrastructure.

Corporate Governance

Legal Proceedings

• The company is not currently a party to or aware of any legal proceedings that are believed to have a material adverse effect on its business, financial condition, or results of operations.

Stakeholder Impact

• Shareholders face potential dilution from future equity financings and increased risk due to significant losses, cash burn, and projected covenant breach.
• Employees may experience increased workload due to expanded headcount and commercialization efforts, but also potential uncertainty if financing is not secured.
• Customers benefit from continued product development and commercialization of TULSA-PRO and Sonalleve, supported by 'Genius services'.
• Creditors (specifically CIBC) face increased risk due to the projected covenant breach, potentially leading to the debt being declared immediately due and payable.

Next Steps

• Continue commercialization efforts for TULSA-PRO and Sonalleve globally.
• Continue investment in clinical trial initiatives, including increased enrollment for the CAPTAIN trial.
• Remediate the identified material weakness in internal control over financial reporting, with completion expected during 2025.
• Seek additional financing or execute other strategic options by Q3 2026 to fund future strategic plans.
• Monitor and address the projected violation of the CIBC Credit Agreement covenant by December 31, 2025.

Key Dates

Recommendation

The company's financial performance for Q2 and H1 2025 shows significant deterioration, with net losses more than doubling and cash burn accelerating. The explicit disclosure of a projected breach of a key financial covenant by year-end and the stated dependence on securing additional financing by Q3 2026 highlight substantial liquidity and operational risks. While revenue growth for the six-month period and improved gross margins are positive, they are insufficient to offset the magnitude of increased operating expenses and the widening losses. The material weakness in internal controls further adds to the investment uncertainty. A seasoned investor would likely view these factors as strong indicators of financial distress and recommend selling to mitigate exposure to these elevated risks.

Keywords

Profound Medical, TULSA-PRO, Sonalleve, medical device, MRI-guided ultrasound, prostate ablation, uterine fibroids, Q2 2025 results, SEC 10-Q, financial reporting, liquidity risk